U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA
|
|
- Kelley Banks
- 8 years ago
- Views:
Transcription
1 Page 35 U.S. DRUG IMPORT BILL HAS SERIOUS IMPLICATIONS FOR CANADA Guy W. Giorno, Lynne Golding, Vincent Routhier, and Philippe David Fasken Martineau DuMoulin LLP INTRODUCTION Legislation currently before the United States Congress could negatively affect the supply and price of prescription drugs in this country, unless Canadian officials take steps to address the situation. At issue is a House of Representatives bill, 1 H.R. 2427, the Pharmaceutical Market Access Act of 2003, that would permit the re-importation of prescription drugs from Canada into the United States. If the legislation passes the Senate and is implemented, then the consequences could include higher prices for brandname drugs sold in Canada, or supply shortages in the Canadian market. BACKGROUND At present the U.S. pharmaceutical industry sells prescription drugs in Canada at prices substantially lower than those south of the border. 2 A 30-year old federal law prohibits re-importation or "gray market" trades. Under the Federal Food, Drug, and Cosmetic Act, a drug manufactured in the United States and exported to a foreign country may not be re-imported to the U.S. except by the drug's own manufacturer. 3 A person other than the manufacturer may reimport only in the event of emergency medical care, and at the discretion of the Secretary of Health and Human Services. 4 In other limited circumstances, individuals may legally import drugs from foreign countries, but only if there is no U.S. substitute for the product. Perhaps the most significant restriction contained in the current law is that drug reimports are only allowed if the H.H.S. Secretary certifies that importation does not create a risk to public safety. Essentially this gives the administration a right of veto over drug imports, as the previous two Secretaries have refused to certify that imports are safe. The bill passed by the House of Representatives would remove the Secretary's effective veto over drug imports. LEGISLATIVE CONTEXT Drug importation is caught up in the much larger issue of Medicare reform. This summer, the Senate and the House of Representatives both passed different Medicare reform bills. 5 A Conference Committee has been working to resolve the differences, with the House Speaker and Senate Majority Leader setting October 17 as the deadline for the Conference to complete its report in time for both houses to vote on the legislation before yearend. As a number of issues remain unresolved, it is possible that no Medicare reform legislation will be agreed to during the current session of the 108th Congress. However, even if legislation is not enacted
2 Page 36 this year, drug importation is a major issue that will not go away. SENATE VERSION The Senate proposal concerning drug importation is part of its larger Medicare reform bill, the Prescription Drug and Medicare Improvement Act of 2003, S. 1. Title VIII of S.1 permits pharmacists and wholesalers to re-import U.S.-manufactured prescription drugs, but only from Canada. 6 In addition, individuals would be allowed to import prescription drugs (up to a 90-day supply) for personal use, provided that they possess a valid prescription and purchase from a licensed Canadian pharmacy registered with the Health and Human Services Secretary. 7 However, all of these new provisions "shall become effective only if the Secretary of Health and Human Services certifies to the Congress that the implementation of this section will (1) pose no additional risk to the public's health and safety; and (2) result in a significant reduction in the cost of covered products to the American consumer." 8 H.H.S. Secretary Tommy Thompson has said that he would not be able to certify the absence of additional risk, meaning that if the legislation passes in this form then Canadian re-imports would still be prohibited. S. 1 would impose a number of safeguards, including the following: Requiring importers to test the drugs for authenticity, degradation and compliance with established specifications and standards. 9 Making each Canadian establishment involved in exporting prescription drugs to the United States register with the H.H.S. Secretary. l0 Imposing strict labeling requirements, including the name and quantity of the active ingredient of the drug, its dosage form, the date on which it was shipped, its point of origin and the price paid. 11 The Senate version would allow the H.H.S. Secretary to cancel the program within 18 months if there is substantial evidence that the detriments of the program outweigh the benefits. 12 HOUSE OF REPRESENTATIVES POSITION During the Conference negotiations, the official House of Representatives negotiating position on the drug re-import issue is reflected by bill H.R. 2427, the Pharmaceutical Market Access Act of There are four key differences between H.R and Title VIII of S. 1: 1. The House bill contains no prerequisite that the Secretary of Health and Human Services certify that implementation would pose no additional risk to health and safety. 2. H.R would allow imports from more than 30 countries, including Canada. 3. The House would allow not just pharmacists and wholesalers but also "qualifying individuals" to import drugs The House bill would force the H.H.S. Secretary to implement the legislation within six months of its passage. 14 H.R also provides that drugs being imported into the United States must be labeled and packaged using counterfeitresistant technologies. 15 These must be
3 Page 37 similar to the technologies used by the Bureau of Engraving and Printing when it prints United States currency, and must be incorporated into multiple elements of the packaging. ADMINISTRATION POSITION Two days before H.R passed, the White House issued a strongly-worded statement of opposition. It called the bill "dangerous legislation" that would expose people to the risk of harm from unsafe or ineffective drugs, would be costly to implement, and would overwhelm the regulatory system of the Food and Drug Administration (F.D.A.). 16 If the Senate version prevails, then the H.H.S. Secretary is not likely to certify that drug reimportation poses no risks, meaning that the new legislation would not take effect. On the other hand, if Congress adopts a law (such as H.R. 2427) that does not require the Secretary's certification that re-imported drugs are safe, then the Administration has promised to implement it. LIKELY OUTCOME At this stage it is uncertain which version of the drug importation rules will appear in the final legislation. Two factors suggest that the House version faces an uphill fight. First, in July, a majority of Senators (53) signed a letter endorsing the requirement that the H.H.S. Secretary certify cost savings and the absence of risk before a law permitting re-importation can take effect. However, signatories later suffered embarrassment when it was revealed that a lobbyist wrote the letter for them; it is unknown whether all of them would still hold to the position contained in the letter. Second, a majority of the House representatives on the Conference Committee originally voted against H.R Thus, despite the House's official position in negotiations with the Senate, it is uncertain how strongly the House members of the Conference Committee will advocate for the House version of drug import legislation. MEANWHILE, IMPORTERS, MANUFACTURERS AND REGULATORS TAKE ACTION Neither supporters nor opponents of drug imports are waiting idly for the Congressional debate to conclude. Imports are increasing, and manufacturers and regulators have responded. Some U.S. consumers and Canadian distributors are currently circumventing the import ban through Internet sales. According to several estimates, Canada is home to more than 100 Internet pharmacies, primarily located in Manitoba, that make low-cost U.S. prescription drugs available to Americans. 17 In response to this growing practise, U.S. pharmaceutical companies such as Pfizer, GlaxoSmithKline and AstraZeneca have begun curtailing the availability of drugs to Canadian distributors and retailers. 18 Drug companies have started to require that their Canadian customers sign undertakings promising not to ship drugs to the United States. Other drug companies have begun carefully monitoring their Canadian customers' purchases, looking for unusual volume increases that could indicate exports to the United States. The cumulative effect of these actions has been substantial price increases for several drugs imported into
4 Page 38 Canada. 19 Meanwhile, acting on behalf of the F.D.A., the U.S. Department of Justice has begun actively enforcing the drug re-importation ban. For example, an injunction was recently sought in U.S. District Court in Oklahoma to prevent Rx Depot and its affiliate, Rx Depot of Canada, from importing prescription drugs from Canada and selling them in the U.S. at reduced prices. 20 Provincial pharmaceutical bodies and the Canadian Medical Association are reminding health care professionals that it is unlawful for them to sell drugs to patients they have not met. For years now, the Manitoba Pharmaceutical Association has been dealing with some members' practise of selling prescription drugs into the United States. 21 Despite increasing scrutiny of drug exports/imports on both sides of the border, the attractiveness of low cost drugs for U.S. consumers remains intense. Even state and municipal governments are considering reimports under health care plans for current and retired state employees. 22 NEGATIVE CONSEQUENCES FOR CANADA Should Congress adopt the drug-import liberalization proposed by H.R (or similar legislation), the implications for Canada could be serious. also have a negative impact on Canadian consumers. The nonpartisan Congressional Budget Office has examined the reimportation issue, and concluded that, "If manufacturers were unable to limit the supply of drugs entering the U.S. market from Canada, the likely result would be that brand-name drug prices in Canada would rise much more than the price in the U.S. would decline. 23 Strong action by domestic authorities would be needed to protect Canadian patients and remedy the U.S. law's adverse effects on Canada. For example, export control licensing requirements could stem the export of prescription drugs. In light of these developments, our Strategic Counsel Practise Group and Health Law Practise Group have been carefully monitoring the issues surrounding cross-border trade in prescription drugs. Fasken Martineau's long-standing relationship with major Canadian pharmaceutical companies (through a dedicated Biotech and Pharma Group) gives us insight into this pressing issue. Further, our experience and expertise in government relations and public policy position us to continue to represent clients' interests effectively as the situation develops Fasken Martineau DuMoulin LLP If significant volumes of drugs are reexported to the United States, then the remaining supply might not be sufficient to meet Canadians' needs. The problem could be exacerbated if manufacturers are forced to curtail products' availability to Canadian retailers. Further, continuing price increases would
5 Page 39 NOTES 1. Passed July 25, 2003, by a vote. 2. Recent studies by Health Canada indicate that drug prices in the United States are 67 percent higher than prices for the same drugs in Canada: "Some Successful Models Ignored as Congress Works on Drug Bill," The New York Times, September 4, U.S.C. 81(d). 4. Id. 5. Medicare Prescription Drug and Modernization Act of 2003, H.R. 1, passed June 27, 2003, on a vote of Prescription Drug and Medicare Improvement Act of 2003, S. 1, passed June 27, 2003, on a vote of Inserted as an amendment to S. 1, adopted June 20, 2003, on a vote. 7. S. 1, Title VIII, Sec. 801(a), enacting Sec. 804(k)(3) of the Federal Food, Drug, and Cosmetic Act. 8. S. 1, Sec. 801(c). The Senate unanimously passed the amendment containing the certification requirement. 9. S. 1, Sec. 801(a), enacting Sec. 804(d) of 10. S. 1, Sec. 80l(a), enacting Sec. 804(f) of 13. H.R. 2427, Sec. 4(1)(b), amending Section 804 of the Federal Food, Drug, and Cosmetic Act. 14. H.R. 2427, Sec. 4(1)(a). 15. H.R. 2427, Sec. 5, amending Title V of the Federal Food, Drug, and Cosmetic Act. 16. Executive Office of the President, Office of Management and Budget, "Statement of Administration Policy: H.R. 2427" (July 23, 2003). 17. "Canada Caught Up in Drug War," The Globe and Mail, September 11, "Canada May Stop Drug Sales to U.S.," The Detroit News, August 13, "Canada's Internet Pharmacies Hurting from Industry Steps to Halt U.S. Sales", The China Post ( September 9, "Feds Target Firm Importing Canadian Drugs", CNN.com, September 11, "E-Pharmacies under Attack: Association Wants Province to Ban Practise", The Winnipeg Free Press, June 16, "Illinois Considers Buying Drugs in Canada", The New York Times, September 16, Congressional Budget Office, Cost Estimate of H.R. 1 and S. 1 (July 22, 2003). 11. S. 1, Sec. 80l(a), enacting Sec. 804(e) of 12. S. 1, Sec. 80l(a), enacting Sec. 804(n) of
5. 16. Health Law in Canada. Constitutional Division of Power
Health Law in Canada Health care in Canada is a complex subject, some health care services are public, some are private and there are a number of different entities involved in regulating and providing
More informationBENEFITS OF PROPOSED DEMOCRATIC MEDICARE DRUG PROGRAM REFORMS IN NEW YORK S 14TH CONGRESSIONAL DISTRICT
UNITED STATES HOUSE OF REPRESENTATIVES COMMITTEE ON GOVERNMENT REFORM MINORITY STAFF SPECIAL INVESTIGATIONS DIVISION OCTOBER 2006 BENEFITS OF PROPOSED DEMOCRATIC MEDICARE DRUG PROGRAM REFORMS IN NEW YORK
More informationGuidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationDrug Re-importation. Julie Kohout
Drug Re-importation By Julie Kohout A bus full of senior citizens makes its way to Canada. These seniors are in search of cheaper prescription medications because they can not afford the prices of their
More informationLaw Firm Compliance: Key Privacy Considerations for Lawyers and Law Firms in Ontario
PRIVACY COMPLIANCE ISSUES FOR LAW FIRMS IN ONTARIO By Sara A. Levine 1 Presented at Law Firm Compliance: Key Privacy Considerations for Lawyers and Law Firms in Ontario Ontario Bar Association, May 6,
More informationAmerican Academy of Physician Assistants
950 North Washington Street Alexandria, VA 22314-1552 703/836-2272 Fax 703/684-1924 TESTIMONY OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS SUBMITTED TO THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TASK
More informationDo No Harm: Congress Should Leave Canadian Prescription Drugs Alone
Submission by the Canadian Pharmacists Association, the Ontario Pharmacists Association, and the Best Medicines Coalition to the Subcommittee on Interstate Commerce, Trade and Tourism of the Senate Committee
More informationWhite Paper. Applying HIPAA s Framework to the Sale and Purchase of Healthcare Receivables
White Paper Applying HIPAA s Framework to the Sale and Purchase of Healthcare Receivables ACA International www.acainternational.org Final October 2007 I. About ACA Applying HIPAA s Framework to the Sale
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES. Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports
This document is scheduled to be published in the Federal Register on 02/08/2013 and available online at http://federalregister.gov/a/2013-02572, and on FDsys.gov 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationUnderstanding Alberta s Drug Schedules
Understanding Alberta s Drug Schedules Preface In May 2002, the provincial drug schedules to the Pharmaceutical Profession Act were amended. In April 2007, the Alberta Regulation 66/2007 to the Pharmacy
More informationThe Unintended Effects of
The Unintended Effects of Healthcare Reform TOM SUROVY, PRINCIPLE COMPLIANCE ATTORNEY CONTENTS CHILD-ONLY POLICIES... 3 PRESCRIPTIONS FOR NONPRESCRIPTION OVER-THE-COUNTER DRUGS... 4 COMMISSIONS FOR INSURANCE
More informationSecurities Trading and Insider Reporting Policy
Securities Trading and Insider Reporting Policy Securities law generally prohibits trading or dealing in the securities of a company on the basis of undisclosed material information. Anyone violating these
More informationForeign Corrupt Practices Act (FCPA): Congressional Interest and Executive Enforcement
Foreign Corrupt Practices Act (FCPA): Congressional Interest and Executive Enforcement Michael V. Seitzinger Legislative Attorney October 21, 2010 Congressional Research Service CRS Report for Congress
More informationMedicare Coverage Gap Discount Program (Filling the Donut Hole)
Medicare Coverage Gap Discount Program (Filling the Donut Hole) Summary: Requires drug manufacturers to provide a 50 percent discount to Part D beneficiaries for brand name drugs and biologics purchased
More informationSASKATCHEWAN COLLEGE OF PHARMACISTS Electronic Transmission of Prescriptions. Policy Statement and Guidelines for Pharmacists
SASKATCHEWAN COLLEGE OF PHARMACISTS Electronic Transmission of Prescriptions PREAMBLE This document replaces the Operational Guidelines - Facsimile Transmission of Prescriptions Current legislation allows
More informationPARLIAMENTARY RESEARCH BRANCH DIRECTION DE LA RECHERCHE PARLEMENTAIRE
PRB 99-38E INSIDER TRADING Margaret Smith Law and Government Division 22 December 1999 PARLIAMENTARY RESEARCH BRANCH DIRECTION DE LA RECHERCHE PARLEMENTAIRE The Parliamentary Research Branch of the Library
More informationSaskTech (Guidance Document) An Evaluation and Monitoring Tool For Pharmacy Assistants
SaskTech (Guidance Document) An Evaluation and Monitoring Tool For Pharmacy Assistants September 2007 1 TABLE OF CONTENTS Page Introduction...3 Pharmacy Assistant/Technician Training Programs... 4 Pharmacy
More informationEnclosure A DEFINITIONS
Enclosure A REBATE AGREEMENT Between The Secretary of Health and Human Services (hereinafter referred to as "the Secretary") and The Manufacturer Identified in Section XI of this Agreement (hereinafter
More informationJay Campbell Executive Director North Carolina Board of Pharmacy
Jay Campbell Executive Director North Carolina Board of Pharmacy I have no relationships with commercial interests related to the content of my presentation. Assessment Questions TRUE or FALSE: The federal
More information1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY
BRIEFING 1083.4 Supply Chain Integrity and Security. A new series of general informational chapters describing various aspects of the pharmaceutical supply chain replaces Good Distribution Practices Supply
More informationSECURITIES TRADING AND INSIDER REPORTING POLICY
SECURITIES TRADING AND INSIDER REPORTING POLICY Securities law generally prohibits trading or dealing in the securities of a company on the basis of undisclosed material information. Anyone violating these
More informationTRADE AGREEMENTS ACT LIMITATIONS ON PROCUREMENT OF PHARMACEUTICALS AND POTENTIAL VA SOLUTIONS
TRADE AGREEMENTS ACT LIMITATIONS ON PROCUREMENT OF PHARMACEUTICALS AND POTENTIAL VA SOLUTIONS Donna Lee Yesner Morgan, Lewis & Bockius, LLP dyesner@morganlewis.com (202)739-5887 The Trade Agreements Act,
More informationComments to Notice of Proposed Amendments to Federal Sentencing Guidelines Federal Register: F.R. Doc. E8-1426 F.R. Publication Date: January 28, 2008
March 27, 2008 VIA HAND DELIVERY Honorable Ricardo H. Hinojosa, Chair United States Sentencing Commission Attention: Public Affairs One Columbus Circle, N.E. Suite 2-500 Washington, DC 20002 Subject: Comments
More informationA Middle Class in the United States? Behind the Counter (BTC) Drugs. Frederick H. Branding, R.Ph., J.D. Rahul Narula
A Middle Class in the United States? Behind the Counter (BTC) Drugs Frederick H. Branding, R.Ph., J.D. Rahul Narula FDA s Regulation of Drugs Federal Food, Drug and Cosmetic Act (FDCA) passed by Congress
More informationAnti-Bribery Provision. 30A of the Securities Exchange Act of 1934. [15 U.S.C. 78dd-1]
Anti-Bribery Provision 30A of the Securities Exchange Act of 1934 [15 U.S.C. 78dd-1] 30A - Prohibited Foreign Trade Practices by Issuers (a) Prohibition It shall be unlawful for any issuer which has a
More informationRegulatory Update Overview of Regulations and Other Developments Regarding PPACA s Employer- Sponsored Group Health Plan Provisions
Reprinted with permission from Employee Benefit Plan Review, March 2011. All rights reserved, WoltersKluwer Company, New York, N.Y. Regulatory Update Overview of Regulations and Other Developments Regarding
More informationExecutive Compensation Issues for Americans Transferring into Canadian Jurisdiction
Executive Compensation Issues for Americans Transferring into Canadian Jurisdiction 01/11Reprinted from Metropolitan Corporate Counsel, November, 2000 by Stuart Aronovitch and Lori Price As the global
More information97TH GENERAL ASSEMBLY State of Illinois 2011 and 2012 SB3197
*LRB0KTG0b* TH GENERAL ASSEMBLY State of Illinois 0 and 0 SB Introduced //0, by Sen. Iris Y. Martinez SYNOPSIS AS New Act INTRODUCED: Creates the Electronic Prescribing Act. Provides that beginning August,
More informationHIPAA Privacy and Security Changes in the American Recovery and Reinvestment Act
International Life Sciences Arbitration Health Industry Alert If you have questions or would like additional information on the material covered in this Alert, please contact the author: Brad M. Rostolsky
More informationDetermining the Bona Fide Nature of Fee-for-Service Arrangements
Determining the Bona Fide Nature of Fee-for-Service Arrangements Mark DeWyngaert, PhD, MBA John Moose, MBA, CPA, ABV Elizabeth Gluck, Esq. September 27, 2012 About the Speakers Elizabeth Gluck, King &
More informationTitle V Preventing Fraud and Abuse. Subtitle A- Establishment of New Health and Human Services and Department of Justice Health Care Fraud Positions
Title V Preventing Fraud and Abuse Subtitle A- Establishment of New Health and Human Services and Department of Justice Health Care Fraud Positions Sec. 501. Health and Human Services Senior Advisor There
More informationThe History of the Legal And Regulatory Issues Surrounding Pharmacy Compounding
The History of the Legal And Regulatory Issues Surrounding Pharmacy Compounding T.C. Spencer Pryor Partner, Alston & Bird LLP FDA & CDC: Collaboration & Challenges FSMA, Food Outbreaks, Pharmacy Compounding
More informationBritish Columbia Justice Reform Initiative Submission
British Columbia Justice Reform Initiative Submission Prepared by the Canadian Bankers Association June 29, 2012 EXPERTISE CANADA BANKS ON LA RÉFÉRENCE BANCAIRE AU CANADA Introduction The Canadian Bankers
More informationNew Federal Regulation of Tax Resolution, Tax Negotiation and Tax Settlement Services: FTC Telemarketing Sales Rule
New Federal Regulation of Tax Resolution, Tax Negotiation and Tax Settlement Services: FTC Telemarketing Sales Rule October 5, 2010, 3:00 4:00 pm ET Jonathan L. Pompan, Esq. Venable LLP, Washington, D.C.
More informationProblems with the Current EPA Policy
U.S. Small Business Administration Office of Advocacy Small Business Regulatory Review and Reform Initiative Nomination of the U.S. Environmental Protection Agency s Affordability Policy under The Safe
More informationElectronic Information Systems
WASHINGTON REPORT Electronic Information Systems New Systems Promote Drug Development and Patient Safety Jill Wechsler FDA expands electronic data submission programs to improve regulatory operations and
More informationCPI CARD GROUP INC. INSIDER TRADING POLICY
CPI CARD GROUP INC. INSIDER TRADING POLICY CPI Card Group Inc. (the Company ) and its Board of Directors have adopted this Insider Trading Policy (this Policy ) both to satisfy our obligation to prevent
More informationVeterinary Compounding
Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),
More informationThe Manitoba Child Care Association PRIVACY POLICY
The Manitoba Child Care Association PRIVACY POLICY BACKGROUND The Manitoba Child Care Association is committed to comply with the legal obligations imposed by the federal government's Personal Information
More informationNavigating company stock regulations with 10b5-1 executive trading plans
RETIREMENT & BENEFIT PLAN SERVICES Workplace Insights Navigating company stock regulations with 10b5-1 executive trading plans Best practices for helping your key executives create well-structured trading
More informationPublic Law 106-95 106th Congress An Act
113 STAT. 1312 PUBLIC LAW 106-95 NOV. 12, 1999 Public Law 106-95 106th Congress An Act N 19 iqqq "^^ amend the Immigration and Nationality Act with respect to the requirements ; for the admission of nonimmigrant
More informationA BILL. To provide a single, universal, comprehensive health insurance benefit for all residents of Illinois, and for other purposes.
Synopsis: This bill expands comprehensive health coverage to all Illinois residents using a single-payer statewide insurance system. Doctors and hospitals remain private, and patients retain their choice
More informationPASSIVE SELLER IMMUNITY FROM PRODUCT LIABILITY ACTIONS. House Bill 4 significantly impacted most areas of Texas Tort Law. In the
PASSIVE SELLER IMMUNITY FROM PRODUCT LIABILITY ACTIONS House Bill 4 significantly impacted most areas of Texas Tort Law. In the traditional products liability arena, tort reform affected three major changes:
More informationMarihuana for Medical Purposes Regulations. October 16, 2014
Marihuana for Medical Purposes Regulations October 16, 2014 Overview Provide an overview of the evolution of marihuana for medical purposes regulations in Canada Status of the old program/ Allard Injunction
More informationTITLE 42 - Section 11601 - Findings and declarations
TITLE 42 - Section 11601 - Findings and declarations CHAPTER 121 INTERNATIONAL CHILD ABDUCTION REMEDIES Sec. 11601. Findings and declarations. 11602. Definitions. 11603. Judicial remedies. 11604. Provisional
More informationMarketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
More informationNovember 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.
CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,
More informationANALYSIS AS REPORTED FROM COMMITTEE
PHARMACY TECHNICIAN LICENSURE S.B. 92 (S-5): ANALYSIS AS REPORTED FROM COMMITTEE Senate Bill 92 (Substitute S-5 as reported by the Committee of the Whole) (as passed by the Senate) Sponsor: Senator Mike
More informationO n Aug. 28, the Department of Health and Human
BNA s Health Law Reporter Reproduced with permission from BNA s Health Law Reporter, 24 HLR 1202, 9/17/15. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com HRSA
More informationTax Research: Understanding Sources of Tax Law (Why my IRC beats your Rev Proc!)
Tax Research: Understanding Sources of Tax Law (Why my IRC beats your Rev Proc!) Understanding Federal Statutes and Legislation Federal statutes provide the foundation of the tax system in the United States.
More information340B Drug Pricing Program. A Survey of the Program s Past, Present, and Future
340B Drug Pricing Program A Survey of the Program s Past, Present, and Future Presented by: Daniel Soldato Wyatt, Tarrant & Combs LLP dsoldato@wyattfirm.com (859) 288-7631 Disclaimer The views expressed
More informationRe: Comments on the Physician Payments Sunshine Act of 2009, S. 301
May 14, 2009 BY ELECTRONIC MAIL The Honorable Charles E. Grassley Ranking Member, Committee on Finance United States Senate 219 Dirksen Senate Office Building Washington, DC 20510-6200 Health_Reform@finance-dem.senate.gov
More informationU.S Department of Defense Standards of Conduct Office
U.S Department of Defense Standards of Conduct Office NON-SENIOR EMPLOYEE POST-GOVERNMENT EMPLOYMENT RESTRICTIONS PURPOSE: This document summarizes the Government ethics rules which may impose certain
More informationCHAPTER 131. SENATE BILL No. 33
CHAPTER 131 SENATE BILL No. 33 AN ACT concerning the state board of pharmacy; pharmacy technicians; terms and membership of the state board of pharmacy; fingerprinting and criminal history record checks;
More informationReview of Maine Pharmacy Rules. An update of new rules adopted 12/11/2013
Review of Maine Pharmacy Rules An update of new rules adopted 12/11/2013 This review is meant to highlight important changes and additions to the rules as adopted on 12/11/2013. We will cover the rules
More informationHow To Clarify The Disclosure Of Information From Prohibited Personnel Practices
PUBLIC LAW 112 199 NOV. 27, 2012 126 STAT. 1465 Public Law 112 199 112th Congress An Act To amend chapter 23 of title 5, United States Code, to clarify the disclosures of information protected from prohibited
More informationS. ll. To improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes. IN THE SENATE OF THE UNITED STATES
114TH CONGRESS 1ST SESSION S. ll To improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes. IN THE SENATE OF THE UNITED STATES llllllllll Mr. HATCH (for himself
More informationWHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain
WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing
More informationLEGISLATURE OF THE STATE OF IDAHO Sixty-second Legislature First Regular Session - 2013 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.
LEGISLATURE OF THE STATE OF IDAHO Sixty-second Legislature First Regular Session - 0 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. BY HEALTH AND WELFARE COMMITTEE 0 0 AN ACT RELATING TO THE HEALTH INSURANCE
More informationAdvancing Online Drug Safety: FDA Perspective
Advancing Online Drug Safety: FDA Perspective Leigh Verbois, PhD Acting Deputy Director Division of Supply Chain Security Office of Drug Security, Integrity, and Recalls Office of Compliance Center for
More informationChief Clerk of the Assembly. Secretary of the Senate. Private Secretary of the Governor
Assembly Bill No. 22 Passed the Assembly September 8, 2011 Chief Clerk of the Assembly Passed the Senate September 8, 2011 Secretary of the Senate This bill was received by the Governor this day of, 2011,
More information7/16/2010. 14 th Annual 340B Coalition Conference July 19, 2010 Washington, DC. Safety Net Hospitals for Pharmaceutical Access
Safety Net Hospitals for Pharmaceutical Access The Story From Washington, D.C. Ted Slafsky Executive Director, SNHPA Editor in Chief, Drug Discount Monitor (202)552-58605860 ted.slafsky@snhpa.org 14 th
More informationInterplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation
Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal
More informationWaste and inefficiency in the Bush Medicare prescription drug plan: Allowing Medicare to negotiate lower prices could save $30 billion a year
Waste and inefficiency in the Bush Medicare prescription drug plan: Allowing Medicare to negotiate lower prices could save $30 billion a year By Roger Hickey & Jeff Cruz In cooperation with Dean Baker,
More informationPHARMACISTS AND PHARMACY TECHNICIANS PROFESSION REGULATION
Province of Alberta HEALTH PROFESSIONS ACT PHARMACISTS AND PHARMACY TECHNICIANS PROFESSION REGULATION Alberta Regulation 129/2006 With amendments up to and including Alberta Regulation 90/2011 Office Consolidation
More informationPetitioner, Respondents.
No. 12-416 IN THE Supreme Court of the United States FEDERAL TRADE COMMISSION, Petitioner, v. WATSON PHARMACEUTICALS, INC., et al., Respondents. ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS
More informationLabour Mobility Act QUESTIONS AND ANSWERS
Labour Mobility Act QUESTIONS AND ANSWERS Background: Agreement on Internal Trade... 1 Background: Labour Mobility Act... 3 Economic Impacts... 5 Role of Professional and Occupational Associations... 5
More informationMARIJUANA DISPENSARIES IN VANCOUVER There ought to be a (Valid)Law LEGAL DISCLAIMER-1
MARIJUANA DISPENSARIES IN VANCOUVER There ought to be a (Valid)Law LEGAL DISCLAIMER-1! I don t speak for the Law Society of BC or Simon Fraser University or Thompson Rivers University or the Globe and
More informationMr. Thomas Arthur Emory University School of Law, Atlanta, GA Dean. Testimony Mr. Chairman, and Members of the Committee:
Mr. Thomas Arthur Emory University School of Law, Atlanta, GA Dean Testimony Mr. Chairman, and Members of the Committee: I am pleased to be here today to discuss with you the important constitutional,
More informationTHE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234
THE STATE EDUCATION DEPARTMENT / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234 TO: FROM: The Professional Practice Committee Douglas E. Lentivech SUBJECT: Proposed Amendment of the Regulations
More informationForeign Corrupt Practices Act Amendments 1
Foreign Corrupt Practices Act Amendments 1 Appendix E SEC. 5001. SHORT TITLE. This part may be cited as the Foreign Corrupt Practices Act Amendments of 1988. SEC. 5002. PENALTIES FOR VIOLATIONS OF ACCOUNTING
More informationOIG Provides Guidance on Internet Advertising Under the Anti-Kickback Law
NUMBER 230 FROM THE LATHAM & WATKINS HEALTH CARE PRACTICE GROUP BULLETIN NO. 230 OCTOBER 25, 2002 OIG Provides Guidance on Internet Advertising Under the Anti-Kickback Law This Advisory Opinion offers
More informationJuly 2, 2008. Ms. Mary Rupp Secretary of the Board National Credit Union Administration 1775 Duke Street Alexandria, VA 22314-3428
1120 Connecticut Avenue, NW Washington, DC 20036 1-800-BANKERS www.aba.com World-Class Solutions, Leadership & Advocacy Since 1875 Keith Leggett Senior Economist Tel: 202-663-5506 Fax: 202-828-4547 Email:
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationThe Jack Layton and Canada s NDP Health Care Debate
Jack Layton New energy. A positive choice. Platform 2004 Health 1 Building an innovative, public health care system Throughout the 1990s, Canadians were told the debate over public health care was about
More informationAnti-Bribery and Books & Records Provisions of. The Foreign Corrupt Practices Act. Current through Pub. L. 105-366 (November 10, 1998)
[As of July 22, 2004] Anti-Bribery and Books & Records Provisions of The Foreign Corrupt Practices Act Current through Pub. L. 105-366 (November 10, 1998) UNITED STATES CODE TITLE 15. COMMERCE AND TRADE
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
More informationPHARMACY TECHNICIAN LICENSURE S.B. 92: ANALYSIS AS ENACTED
PHARMACY TECHNICIAN LICENSURE S.B. 92: ANALYSIS AS ENACTED Senate Bill 92 (as enacted) PUBLIC ACT 285 of 2014 Sponsor: Senator Mike Green Senate Committee: Regulatory Reform House Committee: Health Policy
More informationThis Policy is not intended to replace your individual responsibility to understand and comply with the legal prohibitions against insider trading.
INSIDER TRADING POLICY DOCUMENT REFERENCE REVISION NUMBER TOTAL PAGES ORIGINAL ISSUE DATE EFFECTIVE DATE 3 11 October 25, 1995 November 11, 2014 SCOPE: This Policy is applicable to every employee of Barrick
More informationHIPAA Privacy and Business Associate Agreement
HR 2011-07 ATTACHMENT D HIPAA Privacy and Business Associate Agreement This Agreement is entered into this day of,, between [Employer] ( Employer ), acting on behalf of [Name of covered entity/plan(s)
More informationModel Business Associate Agreement
Model Business Associate Agreement Instructions: The Texas Health Services Authority (THSA) has developed a model BAA for use between providers (Covered Entities) and HIEs (Business Associates). The model
More information247 CMR: BOARD OF REGISTRATION IN PHARMACY
247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,
More informationSTEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005
STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 VerDate 14-DEC-2004 06:53 Jan 05, 2006 Jkt 039139 PO 00000 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL129.109 APPS10 PsN: PUBL129 119 STAT. 2550 PUBLIC LAW
More informationTHE SEC S NEW DODD-FRANK ADVISERS ACT RULEMAKING: AN ANALYSIS OF THE SEC S IMPLEMENTATION OF TITLE IV OF THE DODD-FRANK ACT
THE SEC S NEW DODD-FRANK ADVISERS ACT RULEMAKING: AN ANALYSIS OF THE SEC S IMPLEMENTATION OF TITLE IV OF THE DODD-FRANK ACT Kenneth W. Muller, Jay G. Baris and Seth Chertok* The Investment Advisers Act
More informationWelcoming Remarks. Financial Interdependence in the World s Post-Crisis Capital Markets. Charles I. Plosser
Welcoming Remarks Financial Interdependence in the World s Post-Crisis Capital Markets Presented by GIC in partnership with the Philadelphia Council for Business Economics, the CFA Society of Philadelphia,
More informationSNHPI Safety Net Hospitals for Pharmaceutical Access
SNHPI Safety Net Hospitals for Pharmaceutical Access Why the 340B Program Will Continue to be Important and Necessary after Health Care Reform is Fully Implemented Since 1992, the 340B drug discount program
More informationCROSS-BORDER INSOLVENCY PROTOCOL FOR 360NETWORKS INC. AND ITS AFFILIATED COMPANIES
CROSS-BORDER INSOLVENCY PROTOCOL FOR 360NETWORKS INC. AND ITS AFFILIATED COMPANIES 1. Certain defined terms used in this Protocol shall have the meanings assigned to them in Appendix A. 2. The 360 Group
More informationPHARMACEUTICAL AND BIOTECHNOLOGY LIABILITY INSURANCE APPLICATION
PHARMACEUTICAL AND BIOTECHNOLOGY LIABILITY INSURANCE APPLICATION THIS APPLICATION IS FOR A CLAIMS MADE POLICY. FOR PURPOSES OF THE INSURANCE COMPANIES ACT (CANADA), THIS DOCUMENT WAS ISSUED IN THE COURSE
More informationIACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013
Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is
More informationSubmission to the. Services Task Force on Drug Importation. May 14,2004
The Ontario College of Pharmacists Submission to the Health and Human Services Task Force on Drug Importation May 14,2004 Established under the Pharmacy Act of 1871 the Ontario College of Pharmacists is
More informationCrete-Monee Middle School U.S. Constitution Test Study Guide Answers 2010-2011
Crete-Monee Middle School U.S. Constitution Test Study Guide Answers 2010-2011 1. What is the more common name for the first ten amendments to the constitution? Bill of Rights 2. The introduction to the
More informationHealth Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists
Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists October 2001 In response to pharmacists questions about
More informationWellDyneRx Mail Service General Questions and Answers
WellDyneRx Mail Service General Questions and Answers I. Location/ Hours of Operation 1. Where is WellDyneRx Mail Pharmacy located? WellDyneRx mail pharmacy has two locations: 1) Centennial, CO, a suburb
More informationHere in Oklahoma we have an interesting story to tell. Our economy is growing through sectors
HEALTH CARE It goes without saying that health care reform remains the focus of a great deal of debate and attention even after all the years since the Patient Protection and Affordable Care Act, or Obamacare,
More informationOffice of Professional Regulation & Department of Children and Families. Report on the Use of the Term Social Worker
Office of Professional Regulation & Department of Children and Families Report on the Use of the Term Social Worker I. Introduction Over the last three years OPR has worked with its social worker advisors
More informationThe United States Federal Trade Commission ("FTC") and the Office of the Data Protection Commissioner of Ireland (collectively, "the Participants"),
MEMORANDUM OF UNDERSTANDING BETWEEN THE UNITED STATES FEDERAL TRADE COMMISSION AND THE OFFICE OF THE DATA PROTECTION COMMISSIONER OF IRELAND ON MUTUAL ASSISTANCE IN THE ENFORCEMENT OF LAWS PROTECTING PERSONAL
More informationVETERANS CLAIMS ASSISTANCE ACT OF 2000
PUBLIC LAW 106 475 NOV. 9, 2000 VETERANS CLAIMS ASSISTANCE ACT OF 2000 VerDate 11-MAY-2000 06:07 Dec 06, 2000 Jkt 089139 PO 00475 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL475.106 APPS27 PsN: PUBL475
More informationData Management: Considerations for Integrating Compliance Requirements At Home and Abroad. Toronto, Ontario June 14, 2005
Data Management: Considerations for Integrating Compliance Requirements At Home and Abroad Toronto, Ontario June 14, 2005 Outsourcing Update: New Contractual Options and Risks Lisa K. Abe June 14, 2005
More informationHow To Understand The Constitution Of The United States
APPENDIX C GLOSSARY OF LEGISLATIVE TERMS ACT A bill or measure after it has passed one or both chambers. Also used to denote a law in place. ACTION A description of a step that a bill undergoes as it moves
More informationDOES OHIO S HEALTH CARE FREEDOM AMENDMENT PROHIBIT IT FROM ENACTING AN OBAMACARE EXCHANGE?
DOES OHIO S HEALTH CARE FREEDOM AMENDMENT PROHIBIT IT FROM ENACTING AN OBAMACARE EXCHANGE? Maurice A. Thompson March 26, 2012 Introduction: Ohio Cannot and Must not Implement an Exchange. On March 22,
More information